David Kirk is a freelance writer and communications consultant with interests in synthetic biology, biotech, and sustainability. He has a PhD in molecular microbiology and has industrial experience developing living medicines.
The UK company Exscientia will use its AI-driven drug discovery platform to examine a collection of 15,000 potential coronavirus disease treatments in collaboration with the US research institute Calibr and the non-profit synchrotron company Diamond Light Source. The team’s huge collection of drug molecules will be provided by Calibr, part of the US medical institute […]
The Japanese heavyweight Ono Pharmaceutical has recruited Numab Therapeutics for a second time to co-develop a multi-specific antibody cancer treatment in a deal worth up to €246M (CHF 260M). The announcement follows a two-year collaboration between Ono and Numab announced in March 2017. Under the new agreement, which includes upfront and milestone payments, Ono has […]
Synthetic biology research is strong in Europe, but the region has much to learn from the US when it comes to commercial translation, attracting investment and liaising with regulators. Europe’s synthetic biology scene is on the cusp of maturity. European teams dominated many areas in the overgraduate category at the International Genetically Engineered Machine (iGEM) […]